India, March 4 -- Shares of Quoin Pharmaceuticals Ltd. (QNRX) jumped over 20% on Monday after the company announced that the FDA has cleared recruitment of teen subjects into both ongoing Netherton Syndrome clinical studies.
QNRX is currently trading at $3.4250, up $0.6150 or 21.8861%, on a volume of 24 million shares, above average volume of 30 thousand shares, on the Nasdaq. The stock opened its trading at $5.9200 after closing Friday at 2.8100. The stock has traded between $2.2510 and $12.0000 in the 52 weeks.
FDA cleared the recruitment of teen subjects aged 14 years and older into the company's two ongoing clinical trials for QRX003, which is being developed as a potential treatment for Netherton Syndrome (NS).
Both trials are being...